[Inhibitory action amlexanox on interleukin-3-induced enhancement of histamine releasability of human leukocytes].
Amlexanox, an anti-allergic drug, showed a concentration-dependent inhibition against hrIL-3-induced enhancement of in vitro histamine release from human leukocytes by anti-IgE. The significant inhibitory action of amlexanox was observed in one out of nine and six out of nine allergic subjects at concentrations of 10(-5) M and 10(-4) M, respectively. This means that the inhibitory effect of amlexanox varied from patient to patient. Post-treatment as well as simultaneous treatment with amlexanox produced an inhibitory action on the enhancing effect of hrIL-3, suggesting that hrIL-3-induced enhancement of releasability is a reversible reaction. AA-861, OKY-046, superoxide dismutase and prostaglandin E2 showed no effects on the hrIL-3-induced enhancement of histamine releasability. The inhibitory action of amlexamox to the hrIL-3-induced enhancement of histamine releasability may be a new anti-allergic mechanism, details of which remains unclear.
Urisu
A
A
Department of Pediatrics, Fujita Health University School of Medicine.
Iimi
K
K
Kondo
Y
Y
Horiba
F
F
Masuda
S
S
Tsuruta
M
M
Yazaki
T
T
Torii
S
S
D000328:Adult; D000631:Aminopyridines / Q000494:pharmacology*; D001249:Asthma / Q000276:immunology*; D004357:Drug Synergism; D005260:Female; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D007073:Immunoglobulin E / Q000494:pharmacology; D007377:Interleukin-3 / Q000494:pharmacology*; D007962:Leukocytes / Q000276:immunology; D008297:Male; D011994:Recombinant Proteins / Q000494:pharmacology; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology*; D013189:SRS-A / Q000037:antagonists & inhibitors
D000631:Aminopyridines; D007377:Interleukin-3; D011994:Recombinant Proteins; D013189:SRS-A; D007073:Immunoglobulin E; C045742:amlexanox